Some recommendations for the standardised application and interpretation of molecular assays in NSCLC have been suggested for the clinical trial setting.27 In addition, preliminary laboratory performance guidelines for assessment of the EGFR FISH assay in the stratification of patients with NSCLC have been reported.28 However, detailed guidelines for correctly performing and interpreting the EGFR FISH assay are needed to ensure the high reproducibility and portability between testing laboratories, as these are crucial for the successful clinical application of the assay. This evidence concerns the gene EGFR and non-small cell lung carcinoma.